Andrew Satz is the CEO and Co-Founder of EVQLV, a technology startup leveraging AI to accelerate the speed at which healing reaches those in need. A seasoned technologist and data scientist by training, Satz’s expertise covers artificial intelligence and machine learning, translating data science and tech to solve real world problems, and pharmaceuticals. Satz is a lifelong entrepreneur, having previously founded multiple startups and holding leadership roles in companies ranging from insurance to biotech. Prior to EVQLV, Satz worked with his EVQLV co-founder, Brett Averso, at a Biotech where they worked on strategy, development, supply chain, operations, regulation. Satz holds a BA in Economics-Philosophy and an MSc in Data Science, both from Columbia University.
AI-generated candidates against COVID-19
EVQLV is focused on developing treatments for cancer and auto-immune disorders. Following the outbreak of COVID, the team quickly shifted their technology to address the pandemic. Using a wide range of machine learning algorithms, EVQLV generated and filtered out millions of novel treatments for COVID-19 with a higher probability of success. They did this by measuring and leveraging biological rules and unseen patterns. EVQLV is collaborating with laboratories to produce and test their AI-generated candidates against COVID-19. During their presentation, they will explain how they were able to quickly shift their technology to address COVID-19, the challenges and benefits of using data science and AI to discover and develop drugs, and what you need to know to enter the intersection of AI and life science.
EVQLV Blurb: EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, to accelerate the speed at which biologic therapies reach patients. Our expertise in machine learning, computational biology, software engineering, and preclinical/clinical development strengthens our mission of transforming how healing reaches those in need.